Karyopharm Therapeutics (KPTI) is Initiated by Canaccord Genuity to Buy, Price Target at $20

Karyopharm Therapeutics (KPTI) is Initiated by Canaccord Genuity to Buy according to the research report released to the investors. The brokerage firm has set the Price Target of the shares at $20. The shares recommendation by the Brokerage Firm was released on Dec-22-2015.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) : On Thursday heightened volatility was witnessed in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) which led to swings in the share price. The shares opened for trading at $13.87 and hit $14 on the upside , eventually ending the session at $13.72, with a gain of 0.15% or 0.02 points. The heightened volatility saw the trading volume jump to 207,774 shares. The 52-week high of the share price is $39.6812 and the company has a market cap of $490 million. The 52-week low of the share price is at $10 .

During the last several months other analysts have commented on the company rating. In a research note released to the investors, Leerink Swann maintains its rating on Karyopharm Therapeutics Inc. (NASDAQ:KPTI).The analysts at the brokerage house have a current rating of Outperform on the shares. In a recent information released to the investors, Leerink Swann lowers the new price target from $41 per share to $36 per share. The rating by the firm was issued on November 10, 2015.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has received a short term rating of hold from research analysts at Zacks with a rank of 3. The company has been rated an average of 1.4 by 5 Wall Street Analysts. 4 analysts have added the shares in their list of strong buys. 1 broker firms have advised hold.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI): The mean short term price target for Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has been established at $28 per share. The higher price target estimate is at $38 and the lower price target estimate is expected at $20 according to 5 Analyst. The stock price is expected to vary based on the estimate which is suggested by the standard deviation value of $8.6

Karyopharm Therapeutics, Inc. has lost 9.44% in the last five trading days and dropped 14.78% in the last 4 weeks. Karyopharm Therapeutics, Inc. has dropped 8.17% during the last 3-month period . Year-to-Date the stock performance stands at -63.34%.

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The Company has discovered and developed small molecule, Selective Inhibitors of Nuclear Export (SINE), compounds that inhibit the nuclear export protein XPO1. The Company’s drug candidate, Selinexor (KPT-330), is an XPO1 inhibitor, evaluated in multiple open-label Phase 1 clinical trials in patients with heavily pretreated relapsed or refractory hematological and solid tumor malignancies. As of September 20, 2013, the Company had administered Selinexor to over 170 patients in these trials.